Last 46 quarters of trend data · Healthcare · Drug Manufacturers - General
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Johnson & Johnson's quarterly P/E stands at 21.2x, down 41.7% year-over-year — suggesting improving earnings relative to price. EV/EBITDA has compressed 8.6% YoY to 13.1x, reflecting multiple compression or accelerating EBITDA.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 38.79 | 21.19 | 16.64 | 9.01 | 25.72 | 36.35 | 18.93 | 29.51 | 23.46 | 3.81 | 21.11 | — | 33.20 |
| — | -41.7% | -12.1% | -69.5% | +9.6% | +853.2% | -10.3% | — | -29.3% | -84.3% | -15.3% | — | +37.4% | |
| P/S Ratio | 6.09 | 4.55 | 3.88 | 4.53 | 3.91 | 4.36 | 3.94 | 4.49 | 4.45 | 4.65 | 5.05 | 4.83 | 4.96 |
| — | +4.3% | -1.5% | +0.8% | -12.2% | -6.2% | -21.9% | -7.0% | -10.3% | -14.5% | +1.3% | -4.7% | +7.8% | |
| P/B Ratio | 7.63 | 5.51 | 4.70 | 5.08 | 4.92 | 5.59 | 4.95 | 5.49 | 5.54 | 5.58 | 5.69 | 5.70 | 6.13 |
| — | -1.4% | -5.1% | -7.5% | -11.1% | +0.2% | -13.0% | -3.7% | -9.6% | -4.3% | -9.3% | -10.4% | -0.7% | |
| P/FCF | 27.28 | 13.02 | 37.17 | 29.48 | 18.19 | 17.14 | 19.00 | 33.72 | 15.18 | 15.22 | 35.53 | 42.17 | 31.26 |
| — | -24.1% | +95.6% | -12.6% | +19.8% | +12.6% | -46.5% | -20.0% | -51.4% | -25.3% | +40.0% | +19.7% | +18.2% | |
| EV / EBITDA | 18.78 | 13.07 | 11.45 | 12.72 | 15.89 | 14.30 | 10.98 | 12.13 | 15.06 | 12.69 | 13.84 | 13.46 | 21.90 |
| — | -8.6% | +4.3% | +4.8% | +5.5% | +12.8% | -20.7% | -9.9% | -31.3% | -18.1% | -9.1% | -14.7% | +16.3% | |
| EV / EBIT | 25.01 | 15.44 | 14.74 | 7.42 | 22.65 | 28.86 | 15.40 | 25.37 | 19.51 | 18.83 | 17.59 | — | 28.40 |
| — | -46.5% | -4.3% | -70.8% | +16.1% | +53.3% | -12.5% | — | -31.3% | -13.6% | -17.4% | — | +16.8% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Johnson & Johnson's operating margin was 29.6% in Q3 2025, up 0.9 pp QoQ and up 6.1 pp YoY. The trailing four-quarter average of 26.0% lags the current quarter, suggesting the recent improvement is above-trend.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 69.1% | 69.6% | 67.9% | 66.4% | 68.3% | 69.0% | 69.4% | 69.6% | 68.2% | 69.1% | 70.0% | 68.0% | 67.2% |
| — | +0.8% | -2.2% | -4.5% | +0.2% | -0.1% | -0.8% | +2.3% | +1.5% | -0.1% | +4.4% | +0.6% | -1.0% | |
| Operating Margin | 24.9% | 29.6% | 28.7% | 28.8% | 17.1% | 23.5% | 29.7% | 29.3% | 21.5% | 29.0% | 29.5% | 29.9% | 16.5% |
| — | +25.9% | -3.3% | -1.9% | -20.8% | -19.1% | +0.4% | -1.9% | +30.7% | +2.5% | +9.7% | +14.5% | -8.7% | |
| Net Margin | 15.8% | 21.5% | 23.3% | 50.2% | 15.2% | 12.0% | 20.9% | 15.2% | 18.9% | 121.9% | 23.9% | -0.3% | 14.8% |
| — | +79.1% | +11.7% | +230.0% | -19.5% | -90.2% | -12.7% | +4776.6% | +27.5% | +446.8% | +19.3% | -101.5% | -22.2% |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 20.1% | 6.5% | 7.1% | 14.7% | 4.8% | 3.8% | 6.6% | 4.7% | 5.8% | 35.3% | 7.0% | -0.1% | 4.6% |
| — | +71.8% | +6.8% | +213.5% | -16.2% | -89.2% | -5.2% | +5192.7% | +24.4% | +497.0% | +9.6% | -101.3% | -29.2% | |
| ROA | 8.1% | 2.7% | 2.9% | 5.9% | 1.9% | 1.5% | 2.7% | 1.9% | 2.4% | 14.6% | 2.7% | -0.0% | 1.9% |
| — | +77.9% | +7.8% | +206.9% | -21.1% | -89.7% | +0.0% | +5501.1% | +25.0% | +475.8% | -1.8% | -101.2% | -25.9% | |
| ROIC | 20.7% | 4.9% | 5.0% | 5.4% | 3.4% | 4.5% | 6.0% | 6.1% | 4.4% | 5.1% | 4.6% | 4.5% | 2.9% |
| — | +7.6% | -16.0% | -11.8% | -22.6% | -10.8% | +29.3% | +35.4% | +48.8% | +16.0% | -6.6% | -6.5% | -21.1% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Johnson & Johnson's Debt/EBITDA ratio is 5.2x, down from 5.8x last quarter — elevated, raising questions about debt serviceability. Debt/Equity has declined for 3 consecutive quarters, reflecting a deleveraging trend.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.51 | 0.58 | 0.65 | 0.67 | 0.51 | 0.51 | 0.58 | 0.48 | 0.43 | 0.42 | 0.60 | 0.75 | 0.52 |
| — | +13.4% | +11.5% | +39.3% | +20.1% | +21.3% | -2.8% | -35.7% | -17.4% | -2.2% | +39.8% | +68.3% | +13.2% | |
| Debt / EBITDA | 1.24 | 5.16 | 5.80 | 6.47 | 6.39 | 5.02 | 4.92 | 4.16 | 4.55 | 3.73 | 5.50 | 6.51 | 6.98 |
| — | +2.8% | +18.0% | +55.7% | +40.4% | +34.6% | -10.6% | -36.1% | -34.9% | -14.5% | +38.6% | +54.9% | +30.7% | |
| Current Ratio | 1.11 | 1.07 | 1.01 | 1.26 | 1.11 | 1.03 | 1.07 | 1.17 | 1.16 | 1.21 | 1.12 | 1.07 | 0.99 |
| — | +4.4% | -6.2% | +7.5% | -3.9% | -15.0% | -4.1% | +9.7% | +16.6% | -15.5% | -21.5% | -23.4% | -26.5% | |
| Quick Ratio | 0.86 | 0.80 | 0.76 | 1.03 | 0.86 | 0.79 | 0.85 | 0.94 | 0.91 | 0.96 | 0.88 | 0.85 | 0.81 |
| — | +1.3% | -10.4% | +10.5% | -5.6% | -18.0% | -3.8% | +9.6% | +13.3% | -18.5% | -24.7% | -25.0% | -27.9% | |
| Interest Coverage | 29.34 | 394.22 | 22.11 | 30.88 | 28.04 | 27.35 | 24.66 | 40.47 | 30.51 | 32.28 | 29.30 | 29.46 | 22.06 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 46 years · Updated daily
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
Bull case, key risks, Wall St analyst verdict, and what council investors are saying — updated daily.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorDCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare business quality, growth, and profitability against top sector peers.
Start ComparisonQuick answers to the most common questions about buying JNJ stock.
Johnson & Johnson's current P/E is 38.8x. The average P/E over the last 4 quarters is 18.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Johnson & Johnson's current operating margin is 24.9%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Johnson & Johnson's business trajectory between earnings reports.